2 years ago
LLY
AnalystsRobyn KarnauskasRobyn Karnauskas's Stock Forecasts
AnalystsRobyn Karnauskas
Analyst Ranking
Bottom 23%
#3920 out of 5020 analysts
Average Return
-0.05%
Win Rate
39%57 out of 147
Risk vs Reward
Poor
Good
Robyn Karnauskas's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Bioxcel Therapeutics IncBTAI | +1,137.30% | $71.20 | $880.96 | 2019-11-11 - 2020-11-12 | Strong Buy |
Rayzebio IncRYZB | +212.45% | $20.00 | $62.49 | 2023-10-09 - 2024-02-23 | Strong Buy |
Immunovant IncIMVT | +192.80% | $16.94 | $49.60 | 2020-01-09 - 2021-01-08 | Strong Buy |
Absci CorpABSI | +158.75% | $1.60 | $4.14 | 2023-08-15 - 2024-08-15 | Strong Buy |
Abcellera Biologics IncABCL | +125.12% | $2.03 | $4.57 | 2025-05-15 - 2025-09-17 | Strong Buy |
Robyn Karnauskas Analyst Color
Get additional color on Robyn Karnauskas's coverage of popular stocks
2 years ago
PFE
2 years ago
PFE
2 years ago
LLY
3 years ago
MRK
Robyn Karnauskas's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tourmaline Bio IncTRML | 3 | Hold | $48.00 | +0.63% | Downgrades | 8 days ago |
Abcellera Biologics IncABCL | 2 | Strong Buy | $10.00 | +118.82% | Maintains | 4 months ago |
Amgen IncAMGN | 9 | Hold | $298.00 | +8.48% | Maintains | 8 months ago |
Bristol Myers Squibb CoBMY | 2 | Strong Buy | $65.00 | +40.85% | Maintains | 8 months ago |
Merck & Co IncMRK | 11 | Hold | $110.00 | +35.57% | Downgrades | 8 months ago |
Eli Lilly & CoLLY | 5 | Strong Buy | $1,029.00 | +35.37% | Maintains | a year ago |
Gilead Sciences IncGILD | 10 | Hold | $83.00 | N/A | Maintains | a year ago |
Abbvie IncABBV | 8 | Strong Buy | $210.00 | N/A | Reiterates | a year ago |
Biogen IncBIIB | 13 | Strong Buy | $340.00 | N/A | Maintains | a year ago |
Curis IncCRIS | 2 | Strong Buy | $26.00 | N/A | Maintains | a year ago |
Coherus Biosciences IncCHRS | 11 | Strong Buy | $7.00 | N/A | Maintains | a year ago |
Regeneron Pharmaceuticals IncREGN | 14 | Strong Buy | $1,135.00 | N/A | Maintains | a year ago |
Biomea Fusion IncBMEA | 2 | Strong Buy | $55.00 | N/A | Reiterates | a year ago |
Omniab IncOABI | 2 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Absci CorpABSI | 4 | Strong Buy | $9.00 | N/A | Maintains | a year ago |
Roivant Sciences LtdROIV | 5 | Strong Buy | $23.00 | N/A | Reiterates | a year ago |
Immunovant IncIMVT | 5 | Strong Buy | $48.00 | N/A | Reiterates | a year ago |
Arcus Biosciences IncRCUS | 5 | Strong Buy | $50.00 | N/A | Reiterates | a year ago |
Vertex Pharmaceuticals IncVRTX | 10 | Strong Buy | $508.00 | N/A | Maintains | 2 years ago |
Pfizer IncPFE | 5 | Strong Buy | $36.00 | N/A | Maintains | 2 years ago |
Rayzebio IncRYZB | 1 | Strong Buy | $29.00 | N/A | Initiates Coverage On | 2 years ago |
Ptc Therapeutics IncPTCT | 1 | Hold | $25.00 | N/A | Downgrades | 2 years ago |
Biomarin Pharmaceutical IncBMRN | 5 | Strong Buy | $140.00 | N/A | Reiterates | 2 years ago |
Nucana PLCNCNA | 2 | Strong Buy | $30,000.00 | N/A | Reiterates | 2 years ago |
Fate Therapeutics IncFATE | 3 | Hold | $7.00 | N/A | Reiterates | 2 years ago |
Bioxcel Therapeutics IncBTAI | 5 | Strong Buy | $496.00 | N/A | Maintains | 2 years ago |
Uniqure NvQURE | 1 | Strong Buy | $55.00 | N/A | Maintains | 2 years ago |
Lite Strategy IncLITS | 4 | Hold | N/A | N/A | Downgrades | 3 years ago |
Instil Bio IncTIL | 2 | Strong Buy | $320.00 | N/A | Maintains | 3 years ago |
Kodiak Sciences IncKOD | 3 | Strong Buy | $15.00 | N/A | Maintains | 3 years ago |
Infinity Pharmaceuticals IncINFI | 2 | Strong Buy | $4.00 | N/A | Maintains | 3 years ago |
Deciphera Pharmaceuticals IncDCPH | 3 | Hold | $10.00 | N/A | Downgrades | 4 years ago |
Dicerna Pharmaceuticals IncDRNA | 3 | Hold | $32.00 | N/A | Downgrades | 4 years ago |
Athenex IncATNXQ | 1 | Hold | $120.00 | N/A | Downgrades | 5 years ago |
Opthea LtdOPT | 1 | Strong Buy | $25.00 | N/A | Initiates Coverage On | 5 years ago |
Applied Therapeutics IncAPLT | 1 | Strong Buy | $85.00 | N/A | Initiates Coverage On | 5 years ago |
Celgene CorpCELG | 3 | Hold | $77.00 | N/A | Maintains | 7 years ago |
Alexion Pharmaceuticals IncALXN | 4 | Strong Buy | $190.00 | N/A | Maintains | 7 years ago |
Five Prime Therapeutics IncFPRX | 1 | Strong Buy | $44.00 | N/A | Maintains | 7 years ago |
Acceleron Pharma IncXLRN | 2 | Strong Buy | $63.00 | N/A | Maintains | 8 years ago |
Juno Therapeutics IncJUNO | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Kite Pharma IncKITE | 1 | Hold | $87.00 | N/A | Downgrades | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.